Lutetium Lu-177 Dotatate Flare Reaction.

Purpose: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors, which are progressive and generally metastatic. This therapy is a molecular targeted therapy linking a beta-emitting radioisotope to dotatate, which binds tightly to somatostatin receptors on neuroendocrine tumors cells.

Ten-year outcome after combined modality therapy for inflammatory breast cancer.

Purpose: To evaluate the long-term outcome of combined modality therapy for inflammatory breast cancer.

Methods And Materials: The data from 54 women treated between 1983 and 1996 for inflammatory breast cancer were analyzed. Patients with metastatic disease or disease progression on induction chemotherapy were excluded.